Healios KK

F:6VX

Business Description

Sector

Health Care

Industry

Biotechnology

Headquarters

Japan JP

Employees

75

IPO date

Jun 16, 2015

Healios KK is a Japanese biotechnology company that develops regenerative medicine and cell therapy products. Its core work is to turn living cells into treatments for serious conditions such as stroke and acute respiratory failure, then move those therapies through testing, approval work, and partnering. It is not a traditional drugmaker with a wide catalog of medicines; it is closer to a specialist developer of advanced therapies.

The company earns money mainly through collaboration deals, licensing arrangements, and development payments from partners, with the longer-term goal of selling approved therapies or sharing in sales. Its main customers are not retail buyers but hospitals, physicians, and pharmaceutical partners that help fund, test, manufacture, or distribute its treatments. Because cell therapies are hard to make and regulate, much of the business is built around research, clinical development, and technology transfer rather than large-scale manufacturing.

What makes Healios different is its role in a very early, high-risk part of the healthcare value chain. It focuses on a few targeted therapies and works through partnerships to advance them, which means success depends on clinical results and regulatory approval more than on broad product marketing. That gives it the profile of a focused biotech platform rather than a diversified healthcare company.